#United States #Minneapolis #Bio-Techne #Fiscal 2025 #Exosome Diagnostics

Bio-Techne Corporation Reports Fourth Quarter Results for Fiscal Year 2025

On August 6, 2025, Bio-Techne Corporation (NASDAQ: TECH) released its financial results for the fourth quarter that ended on June 30, 2025. The report reveals some significant insights into the company’s performance amidst ongoing market challenges and strategic shifts.

Key Highlights From the Fourth Quarter

The company showcased a 3% increase in organic revenue for the fourth quarter, amounting to $317.0 million. When accounting for foreign currency impacts and other factors, the reported growth stands at 4%. For the entire fiscal year 2025, Bio-Techne's full-year organic revenue ascended to $1.2 billion, reflecting a consistent growth rate of 5%.

Despite a strong performance in revenue, the financial outlook includes a GAAP (Generally Accepted Accounting Principles) earnings per share (EPS) decline to ($0.11), down from $0.25 in the same quarter last year. Adjusted EPS, however, improved to $0.53 compared to $0.49 in the prior year’s fourth quarter, signaling a resilient operational performance.

Segment Performance

Bio-Techne's distinct segments have brought varying results:

• - Protein Sciences Segment: This segment saw a robust contribution, with net sales climbing to $226.5 million, a 6% hike compared to last year’s $214.0 million. The organic growth rate of 4% was bolstered by favorable currency impacts and ongoing profitability initiatives, leading to an operating margin of 43.6%.

• - Diagnostics and Spatial Biology Segment: This segment faced some challenges, with fourth-quarter sales slightly down to $89.7 million from $90.7 million in the previous year. The decline is attributed to an unfavorable product mix that led to a decrease in operating margin to 6.0%.

Overall, the reconciled figures for the full fiscal year reveal that the Protein Sciences segment generated approximately $870.2 million while the Diagnostics and Spatial Biology segment reached $346.3 million.

Strategic Divestitures and Focus Areas

In a notable strategic move, Bio-Techne announced the divestiture of its Exosome Diagnostics business as part of a drive to enhance profitability and redirect investments towards high-growth areas. This restructuring aims to bolster their focus on non-CLIA based product lines, particularly in therapeutics and diagnostics.

Kim Kelderman, President and CEO, emphasized the importance of this realignment during the earnings call, asserting, “Despite ongoing market uncertainties, our strategic decisions position us for greater profitability and allow us to concentrate on innovation.” The acquisition of new business structures and the transition of strategic leadership are factors that will be vital for navigating market dynamics.

Financial Performance Metrics

Fourth Quarter FY2025 Overview

• - Net Sales: $317.0 million, representing 4% growth (3% organic).
• - GAAP Operating Income: ($23.9 million), noticeably down from $45.8 million last year, mainly due to the impairment of the Exosome Diagnostics business.
• - Adjusted Operating Margin: 32.0% which indicates slight contraction from 33.5% a year prior, affected by product mix disparities.

Full Fiscal Year 2025 Overview

• - Total Revenue: Grew to $1.2 billion, solidifying a sustainable growth trajectory.
• - GAAP EPS: Reported at $0.46, a decline from $1.05 last year amid restructuring and restructuring-related costs.
• - Adjusted EPS: Rose to $1.92 from $1.77.

Bio-Techne's performance in FY2025 has laid foundational elements for innovation with intentions of being leaders in precision diagnostics and therapeutic tools, despite experiencing some headwinds. The company appears optimistic regarding the coming fiscal periods, while stakeholders remain cautious of market volatility and its possible implications on performance.

For further engagement, Bio-Techne will host an earnings conference call on August 6, at 8:00 a.m. CDT. Interested parties can participate via dial-in or access the live webcast, ensuring transparent communication regarding the company’s strategic outlook and performance insights.